netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 13: Skin - Full Chapter
13.06.01  Expand sub section  Topical preparations for acne
13.06.01  Expand sub section  Benzoyl peroxide and azelaic acid
13.06.01  Expand sub section  Topical antibacterials for acne
13.06.01  Expand sub section  Topical retinoids and related preparations for acne
 note 

MHRA advice (June 2019) - Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women

 

Adapalene (Differin)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Differin®Adapalene 0.1% cream 45g
Differin®Adapalene 0.1% gel 45g

 
   
Isotretinoin (Isotrex )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Isotrex®- Isotretinoin 0.05% gel 

Discontinued 

Prescribers to consider alternative topical preparations within the drug class.

 
   
Adapalene with benzoyl peroxide
(Epiduo)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Topical retinoids and related preparations with benzoyl peroxide

Epiduo®- Adapalene 0.1% and benzoyl peroxide 2.5% gel 45g

 
   
Isotretinoin with erythromycin
(Isotrexin)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Topical retinoids and related preparations with antibacterial

Isotrexin®- Isotretinoin 0.05% and erythromycin 2.0% gel 30g

 
   
Tretinoin with clindamycin phosphate
(Treclin)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Topical retinoids and related preparations with antibacterial

Treclin®- Clindamycin phosphate 1% and tretinoin 0.025% gel 30g

 
   
Tretinoin with erythromycin
(Aknemycin Plus)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

Topical retinoids and related preparations with antibacterial

Aknemycin®Plus - Tretinoin 0.025% and erythromycin 4.0% solution, 25ml

 
   
13.06.01  Expand sub section  Other topical preparations for acne to top
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary